AUGUSTINE THERAPEUTICS NV

HQ - Leuven

Summary

Augustine Therapeutics is a biotechnology company focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 65 M

Avg. Deal Size£ 65 M

Market Context

Senior Management

Gerhard Koenig
CEO